Loading
Loading…
Loading…
| # | Company | Amount | Rank | Status |
|---|---|---|---|---|
| 1 | H1₹117.80Admitted-Finance | H1 | Admitted-Finance | |
| 2 | H2₹91.22−₹26.58 (22.6%)Admitted-Finance CIPLA HOUSE PENINSULA BUSINESS PARK GANPATRAO KADAM MARG LOWER PAREL MUMBAI MAHARASHTRA 400013 | MUMBAI | MAHARASHTRA | 400013 | H2 | Admitted-Finance | |
| 3 | H3₹83.79−₹34.01 (28.9%)Admitted-Finance | H3 | Admitted-Finance | |
| 4 | H4₹80.34−₹37.46 (31.8%)Admitted-Finance PLOT NO 2117 A 2 PHASE II II G I D C VAPI GUJARAT INDIA 396195 | VAPI | VALSAD | GUJARAT | 396195 | H4 | Admitted-Finance | |
| 5 | H5₹66.03−₹51.77 (43.9%)Admitted-Finance | H5 | Admitted-Finance |
| Sl No | Description | Qty | Unit | Laurus Labs Limited H10 | Aurobindo Pharma Ltd. H8 | Cipla Ltd H2 | CENTURION LABORATORIES PVT.LTD H5 | Hetero Healthcare Limited H6 | MYLAN LABORATORIES LIMITED H1 | J. DUNCAN HEALTHCARE PVT LTD H7 | MICRON PHARMACEUTICALS H4 | HETERO LABS LIMITED H9 | EMCURE PHARMACEUTICALS LTD. H3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.00ANTI TB DRUGS | |||||||||||||
| 1.01 | Zidovudine 300 mg +Lamivudine 150 mg | 4,30,82,100 | Tablets | - | - | 6.99 ₹7.83 | 6.93 ₹7.76 | 7.65 ₹8.57 | 7.08 ₹7.93 | 6.78 ₹7.59 Lowest | 8.91 ₹9.98 | - | 7.11 ₹7.96 |
| 1.02 | Tenofovir 300 mg +Lamivudine 300 mg + Doultegravir 50 mg | 90,39,99,330 | Tablets | 14.29 ₹16.01 | 12.06 ₹13.51 | 10.98 ₹12.3 Lowest | - | - | 11.9 ₹13.33 | - | - | 11.97 ₹13.41 | 11.65 ₹13.05 |
| 1.03 | Doultegravir 50 mg | 11,54,42,400 | Tablets | - | 6.54 ₹7.32 | 6.18 ₹6.92 | - | - | 5.84 ₹6.54 | - | - | 3.9 ₹4.37 Lowest | 3.91 ₹4.38 |
| 1.04 | Darunavir 600 mg | 2,15,37,000 | Tablets | - | - | 49.41 ₹55.34 | 29.97 ₹33.57 Lowest | 43.85 ₹49.11 | 50 ₹56 | 30.48 ₹34.14 | 44.91 ₹50.3 | - | 35 ₹39.2 |
| 1.05 | Ritonavir 100 mg | 2,16,83,940 | Tablets | - | - | - | 5.94 ₹6.65 Lowest | 7 ₹7.84 | 9.67 ₹10.83 | 6.3 ₹7.06 | 7.92 ₹8.87 | - | 7.89 ₹8.84 |
| 1.06 | Abacavir 120 mg + Lamivudine 60 mg | 5,96,99,370 | Tablets | - | - | - | 2.25 ₹2.52 Lowest | - | 2.48 ₹2.78 | - | - | - | - |
| 1.07 | Lopanavir 100 mg +Ritonavir 25 mg | 1,57,90,680 | Tablets | - | 8.18 ₹9.16 | - | 6.39 ₹7.16 Lowest | - | 8.25 ₹9.24 | 6.72 ₹7.53 | 9.99 ₹11.19 | - | 9.25 ₹10.36 |
| 1.08 | Lopanavir 40 mg+ Ritonavir 10 mg (Pellets/Granules) | 23,11,200 | Capsule/Sachet | - | - | 7.89 ₹8.84 | 7.47 ₹8.37 Lowest | - | 9.95 ₹11.14 | - | - | - | - |
Tender Value
₹1429.3 Cr
EMD Value
₹2.5 L
Closing Date
3 Apr 2020, 3:00 pmClosed
DG and CEO
2nd Floor, Vishwa Yuvak Kendra , Near Teen Murti Marg
Procurement of ARV Drugs
2020_CMSS_543703_1
CMSS/PROC/2019-21/NACO/052
Open Tender
Drugs and Pharmaceutical Products
Fixed-rate
75 days
CMSS
As per tender terms and conditions
2 documents required · 2 mandatory
₹0
₹2.5 L
Yes
New Delhi
3 Jun 2020
11 Feb 2020
3 Apr 2020
11 Feb 2020
3 Apr 2020
25 Feb 2020
11 Feb 2020 - 18 Feb 2020
18 Feb 2020
ANTI TB DRUGS
Zidovudine 300 mg +Lamivudine 150 mg
Tenofovir 300 mg +Lamivudine 300 mg + Doultegravir 50 mg
Doultegravir 50 mg
Darunavir 600 mg
Ritonavir 100 mg
Abacavir 120 mg + Lamivudine 60 mg
Lopanavir 100 mg +Ritonavir 25 mg
Lopanavir 40 mg+ Ritonavir 10 mg (Pellets/Granules)
Cipla Ltd
EMCURE PHARMACEUTICALS LTD.
MICRON PHARMACEUTICALS
CENTURION LABORATORIES PVT.LTD
Hetero Healthcare Limited
J. DUNCAN HEALTHCARE PVT LTD
Aurobindo Pharma Ltd.
HETERO LABS LIMITED
Laurus Labs Limited
stage.html
html • 0.05 MB
tech_bid_open.pdf
tech_eval.pdf
fin_bid_open.pdf
boq_comp_chart.xlsx
xlsx
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
details.html
html • 0.03 MB
Tendernotice_1.pdf
PDF • 0.35 MB
TenderDoc_52.pdf
Tender Documents • 2.27 MB
BOQ_569639.xls
BOQ • 0.28 MB
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .